Although its inhibitors dabrafenib and vemurafenib have demonstrated potential therapeutic efficacy for BRAF-mutant thyroid cancers [22, 23], their widespread utilization in clinical practice has been limited partly due to the emergence of drug resistance [24]. This evidence concerns the gene BRAF and thyroid gland carcinoma.